SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bliss GVS Pharma - Quaterly Results

11 May 2023 Evaluate
A minor change in the total revenue was seen in the March 2023 quarter. The total revenue for the quarter stood at Rs. 1434.19 millions against Rs. 1383.01 millions during year ago period.Net Profit of the company move down -68.04% to Rs. 61.06  millions from Rs. 191.04 millions  in the same quarter last year.The Operating Profit of the company witnessed a decrease to 173.90 millions from 311.15 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 1434.19 1383.01 3.70 5983.40 6363.57 -5.97 5983.40 6363.57 -5.97
Other Income 64.79 124.36 -47.90 507.66 326.28 55.59 507.66 326.28 55.59
PBIDT 173.90 311.15 -44.11 1409.21 1418.26 -0.64 1409.21 1418.26 -0.64
Interest 49.73 15.37 223.55 100.57 43.24 132.59 100.57 43.24 132.59
PBDT 124.17 295.78 -58.02 1308.64 1402.47 -6.69 1308.64 1402.47 -6.69
Depreciation 39.74 34.06 16.68 151.73 138.47 9.58 151.73 138.47 9.58
PBT 84.43 261.72 -67.74 1156.91 1264.00 -8.47 1156.91 1264.00 -8.47
TAX 23.37 70.68 -66.94 302.14 337.36 -10.44 302.14 337.36 -10.44
Deferred Tax -24.69 14.27 -273.02 -42.10 7.68 -648.18 -42.10 7.68 -648.18
PAT 61.06 191.04 -68.04 854.77 926.64 -7.76 854.77 926.64 -7.76
Equity 104.15 103.68 0.45 104.15 103.68 0.45 104.15 103.68 0.45
PBIDTM(%) 12.13 22.50 -46.10 23.55 22.29 5.68 23.55 22.29 5.68

Bliss GVS Pharma Share Price

258.35 -0.95 (-0.37%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×